| Melissa C Bartick, MD | |
|
Cambridge Health Alliance, 1493 Cambridge Street, Cambridge, MA 02139 | |
| (617) 665-1000 | |
| Not Available |
| Full Name | Melissa C Bartick |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 34 Years |
| Location | Cambridge Health Alliance, Cambridge, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841213824 | NPI | - | NPPES |
| 3111393 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 77688 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mount Auburn Hospital | Cambridge, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atrius Health Inc | 4789588641 | 1116 |
News Archive
Careful documentation of a hospice patient's end-of-life wishes - and prominently noting that information in health records early - could prevent unwanted hospitalizations and medical interventions, a new study suggests.
In a massive health relief effort underway in the flood-affected parts of Pakistan, nearly six million people have been treated for health conditions since the floods began in late July; but there are urgent needs to prevent further health crises or food insecurity caused by large-scale damage to crops and agricultural land.
Brian Walker, Ph.D., with the Myeloma Center at the University of Arkansas for Medical Sciences has received a $542,486, three-year grant from the Leukemia & Lymphoma Society to look at changes in the DNA sequence that effects the development and advancement of multiple myeloma, a cancer of plasma cells in the blood.
A study led by researchers at the Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveals how late-stage, hormone-independent prostate tumors gain the ability to grow without need of hormones.
AVANIR Pharmaceuticals, Inc. today announced the electronic publication of the results of the pivotal Phase III STAR trial of its investigational drug AVP-923 (dextromethorphan/quinidine) in the Annals of Neurology. The publication entitled "Dextromethorphan Plus Ultra-Low-Dose Quinidine Reduces Pseudobulbar Affect" evaluated two low dose formulations compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).
› Verified 3 days ago
| Entity Name | Atrius Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871639914 PECOS PAC ID: 4789588641 Enrollment ID: O20031121000582 |
News Archive
Careful documentation of a hospice patient's end-of-life wishes - and prominently noting that information in health records early - could prevent unwanted hospitalizations and medical interventions, a new study suggests.
In a massive health relief effort underway in the flood-affected parts of Pakistan, nearly six million people have been treated for health conditions since the floods began in late July; but there are urgent needs to prevent further health crises or food insecurity caused by large-scale damage to crops and agricultural land.
Brian Walker, Ph.D., with the Myeloma Center at the University of Arkansas for Medical Sciences has received a $542,486, three-year grant from the Leukemia & Lymphoma Society to look at changes in the DNA sequence that effects the development and advancement of multiple myeloma, a cancer of plasma cells in the blood.
A study led by researchers at the Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveals how late-stage, hormone-independent prostate tumors gain the ability to grow without need of hormones.
AVANIR Pharmaceuticals, Inc. today announced the electronic publication of the results of the pivotal Phase III STAR trial of its investigational drug AVP-923 (dextromethorphan/quinidine) in the Annals of Neurology. The publication entitled "Dextromethorphan Plus Ultra-Low-Dose Quinidine Reduces Pseudobulbar Affect" evaluated two low dose formulations compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).
› Verified 3 days ago
| Entity Name | Mt Auburn Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992750996 PECOS PAC ID: 6103725031 Enrollment ID: O20040527001374 |
News Archive
Careful documentation of a hospice patient's end-of-life wishes - and prominently noting that information in health records early - could prevent unwanted hospitalizations and medical interventions, a new study suggests.
In a massive health relief effort underway in the flood-affected parts of Pakistan, nearly six million people have been treated for health conditions since the floods began in late July; but there are urgent needs to prevent further health crises or food insecurity caused by large-scale damage to crops and agricultural land.
Brian Walker, Ph.D., with the Myeloma Center at the University of Arkansas for Medical Sciences has received a $542,486, three-year grant from the Leukemia & Lymphoma Society to look at changes in the DNA sequence that effects the development and advancement of multiple myeloma, a cancer of plasma cells in the blood.
A study led by researchers at the Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveals how late-stage, hormone-independent prostate tumors gain the ability to grow without need of hormones.
AVANIR Pharmaceuticals, Inc. today announced the electronic publication of the results of the pivotal Phase III STAR trial of its investigational drug AVP-923 (dextromethorphan/quinidine) in the Annals of Neurology. The publication entitled "Dextromethorphan Plus Ultra-Low-Dose Quinidine Reduces Pseudobulbar Affect" evaluated two low dose formulations compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).
› Verified 3 days ago
| Entity Name | Cambridge Public Health Commission |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932313228 PECOS PAC ID: 8921910894 Enrollment ID: O20050808000725 |
News Archive
Careful documentation of a hospice patient's end-of-life wishes - and prominently noting that information in health records early - could prevent unwanted hospitalizations and medical interventions, a new study suggests.
In a massive health relief effort underway in the flood-affected parts of Pakistan, nearly six million people have been treated for health conditions since the floods began in late July; but there are urgent needs to prevent further health crises or food insecurity caused by large-scale damage to crops and agricultural land.
Brian Walker, Ph.D., with the Myeloma Center at the University of Arkansas for Medical Sciences has received a $542,486, three-year grant from the Leukemia & Lymphoma Society to look at changes in the DNA sequence that effects the development and advancement of multiple myeloma, a cancer of plasma cells in the blood.
A study led by researchers at the Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveals how late-stage, hormone-independent prostate tumors gain the ability to grow without need of hormones.
AVANIR Pharmaceuticals, Inc. today announced the electronic publication of the results of the pivotal Phase III STAR trial of its investigational drug AVP-923 (dextromethorphan/quinidine) in the Annals of Neurology. The publication entitled "Dextromethorphan Plus Ultra-Low-Dose Quinidine Reduces Pseudobulbar Affect" evaluated two low dose formulations compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa C Bartick, MD 1493 Cambridge St, Cambridge, MA 02139-1047 Ph: (617) 665-1000 | Melissa C Bartick, MD Cambridge Health Alliance, 1493 Cambridge Street, Cambridge, MA 02139 Ph: (617) 665-1000 |
News Archive
Careful documentation of a hospice patient's end-of-life wishes - and prominently noting that information in health records early - could prevent unwanted hospitalizations and medical interventions, a new study suggests.
In a massive health relief effort underway in the flood-affected parts of Pakistan, nearly six million people have been treated for health conditions since the floods began in late July; but there are urgent needs to prevent further health crises or food insecurity caused by large-scale damage to crops and agricultural land.
Brian Walker, Ph.D., with the Myeloma Center at the University of Arkansas for Medical Sciences has received a $542,486, three-year grant from the Leukemia & Lymphoma Society to look at changes in the DNA sequence that effects the development and advancement of multiple myeloma, a cancer of plasma cells in the blood.
A study led by researchers at the Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveals how late-stage, hormone-independent prostate tumors gain the ability to grow without need of hormones.
AVANIR Pharmaceuticals, Inc. today announced the electronic publication of the results of the pivotal Phase III STAR trial of its investigational drug AVP-923 (dextromethorphan/quinidine) in the Annals of Neurology. The publication entitled "Dextromethorphan Plus Ultra-Low-Dose Quinidine Reduces Pseudobulbar Affect" evaluated two low dose formulations compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).
› Verified 3 days ago
Vikas Gampa, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-3600 | |
Miss Janet O Yardley, MD Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 1493 Cambridge St, Macht B10, Cambridge, MA 02139 Phone: 617-665-1000 Fax: 617-665-1976 | |
Abdul Qadir Dar, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 330 Mount Auburn St, Cambridge, MA 02138 Phone: 617-492-3500 | |
Dr. Erica Dwyer, MD, PHD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-3555 | |
Dr. Soumya Narayan, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-1000 | |
Dr. Priyank Jain, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1493 Cambridge St, Cambridge, MA 02139 Phone: 617-665-1000 | |
Jason Glen Lieberthal, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 330 Mount Auburn St, South 4, Room 454, Cambridge, MA 02138 Phone: 617-499-5112 |